ASX Share rice
Thu 06 Aug 2020 - 01:39:am (Sydney)

FPH Share Price


FPH Company Information


Fisher & Paykel Healthcare Corporation Limited




Medical Instruments & Supplies


15 Maurice Paykel Place Auckland New Zealand 2013


64 9 574 0100

Full Time Employees:


MD, CEO & Exec. Director:

Mr. Lewis G. Gradon

Chief Financial Officer:

Ms. Lyndal York

VP of Products & Technology:

Dr. Andrew Somervell

Investor Relations Mang.:

Hayden Brown

Sr. Communications Mang.:

Rachel Reynolds

Company Overview:

Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems worldwide. It provides its products for use in respiratory care, acute care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company offers myAIRVO 2, a humidifier with integrated flow source; Optiflow, a nasal high flow therapy; and noninvasive and invasive ventilation systems. It also provides infant respiratory products, such as resuscitation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. In addition, the company offers hospital products, including humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, data management products, humidifiers, and accessories. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.

FPH Share Price Information

Shares Issued:


Market Capitalisation:


Dividend per Share:


Ex Dividend Date:


Dividend Yield:


Earnings per Share:


Profit Margin:


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


QuarterlyEarnings Growth(YOY):


FPH CashFlow Statement

CashFlow Date:




Change To Liabilities:


Total Cashflow From Investing Activities:


Net Borrowings:


Net Income:


Total Cash From Operating Activities:


Dividends Paid:


Capital Expenditures:


FPH Income Statement

Income Date:


Income Before Tax:


Net Income:


Gross Profit:


Operating Income:


Interest Expense:


Income Tax Expense:


Total Revenue:


Cost Of Revenue:


FPH Balance Sheet

Balance Sheet Date:


Intangible Assets:


Total Liabilities:


Total Stockholder Equity:


Total Assets:


Common Stock:


Retained Earnings:


Other Liabilities:


Other Assets:




Total Current Liabilities:


Property - Plant & Equipment:


Net Tangible Assets:


Total Current Assets:


Long-Term Debt:


Net Receivables:


Short-Term Investments:




Accounts Payable:


Short-Term Investments:


Non Current Liabilities Total:


FPH Share Price History

FPH News

24 Jul, 2020
Lewis Gradon became the CEO of Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) in 2016, and we think it's a...
18 Apr, 2020
Most readers would already be aware that Fisher & Paykel Healthcare's (NZSE:FPH) stock increased significantly by 33...
08 Apr, 2020
(Bloomberg Opinion) -- In the face of a global health emergency, automakers are stepping in — or being summoned — to make ventilators. Can they manufacture at the scale required, with the world needing a 10-fold increase in production to cope with the surge in coronavirus infections? It will be a severe challenge.Car companies such as Ford Motor Co., General Motors Co. and Toyota Motor Corp. are a natural choice to mass-produce these medical devices. They churn out millions of vehicles every year, procuring and bringing together hundreds of parts from around the world at rapid speed. Ventilators needs anything from 400 to 1,000 components from tubes and sensors to pressure valves, humidification systems and filters. There is significant overlap between the engineering of ventilators and cars, which both bring together electronic, electric, hydraulic and mechanical aerodynamics expertise.The parts are mostly different, though. The constituents of a ventilator come from dozens of countries and through as many as nine layers of suppliers. At the same time, some specialty components, such as oxygenation membranes needed for mechanical ventilation, are made by only a few precision manufacturers— meaning that any attempt to effect a rapid expansion in global production is constrained by the ability of these companies to ramp up.The same disruption the coronavirus pandemic has wrought on automakers’ global supply chains will apply equally to their efforts to make ventilators. In normal times, such a switch might be feasible. However, automakers are only in this position because conditions are so abnormal. The coronavirus has wreaked havoc on supply chains. Logistics, transportation and manufacturing have been upended. Retooling factories will take time and the disease won’t wait.That makes the task even more formidable for companies such as Ford and GM, which have faced pressure from President Donald Trump to move more quickly and repurpose factories to turn out ventilators. Trump invoked the wartime Defense Production Act last week to help ventilator manufacturers procure supplies. Still, the administration’s effort doesn’t cover the full chain from raw materials to distribution, as my colleague Brooke Sutherland has written. The U.S. may need as many as 960,000 ventilators, the Society of Critical Care Medicine estimates, versus 200,000 that are available. India’s requirement is as many as 220,000 compared with an estimate of about 25,000 now, according to the Brookings Institution. These numbers depend on the speed of the disease’s spread and the severity of infections, and can change rapidly. Big manufacturers currently produce around 200 ventilators a week and need to make 10 times that number, according to Bloomberg Intelligence industrials and medical equipment analyst Nikkie Lu. The Indian government is urging local automakers to get involved. In the U.K. and Europe, the likes of McLaren Automotive Ltd. and Mercedes AMG High Performance Powertrains Ltd. are helping out.GM is sourcing 419 direct parts from 91 so-called tier-1 suppliers for ventilators made at its Kokomo plant in Indiana. While a significant portion are produced in North America, there are suppliers in more than 10 countries including China. GM is helping increase sourcing capacity within the supply chain of its ventilator partner Ventec Life Systems Inc., and is having to develop new sources of parts in its own.While China is reopening for business and putting a priority on medical equipment, other countries are in lockdown. That’s making it increasingly tough to get the right products to manufacturers, particularly where operations are dispersed. For example, New Zealand ventilator maker Fisher & Paykel Healthcare Corp. sources components from China for manufacture at home and in Mexico. ResMed Inc., a San Diego-based company that makes a ventilator used during the severe acute respiratory syndrome outbreak, does most of its manufacturing in Singapore and Sydney.There are other obstacles. This is a niche industry that’s complex and highly regulated. China has more than 20 mechanical ventilator makers that produce about 2,200 machines a week or about a fifth of total global output; only eight are certified to sell in Europe. Medical devices need to be produced in sterile and clean-room certified conditions. That means converting factories to scale up isn’t a simple matter. In recent weeks, some countries have complained of faulty tests and medical equipment coming from China. Officials there banned the export of medical supplies that don’t meet China’s standards.Then there’s protectionism. Trade barriers are going up in dozens of countries as the world moves into survival mode. Having shipped key medical supplies abroad going into the crisis, the U.S. has now joined the trend, using the defense act to order 3M Co. to halt exports of its protective masks to some nations and prioritize sales to the federal government. The U.S.-China trade war had already showed up the fragility of global supply chains. Covid-19 and the rush to make ventilators will be a telling marker of how effectively they still function. Conditions could hardly be more difficult for such a critical test. This column does not necessarily reflect the opinion of Bloomberg LP and its owners.Anjani Trivedi is a Bloomberg Opinion columnist covering industrial companies in Asia. She previously worked for the Wall Street Journal. For more articles like this, please visit us at now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
23 Mar, 2020
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it...
29 Feb, 2020
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
09 Feb, 2020
Today we'll look at Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) and reflect on its potential as an...
20 Jan, 2020
How far off is Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) from its intrinsic value? Using the most...
31 Dec, 2019
In 2016 Lewis Gradon was appointed CEO of Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH). This analysis...
09 Dec, 2019
Whilst it may not be a huge deal, we thought it was good to see that the Fisher & Paykel Healthcare Corporation...
01 Dec, 2019
Increase in profitability and industry-beating performance can be essential considerations in a stock for some...
01 Nov, 2019
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
12 Oct, 2019
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
21 Sep, 2019
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
19 Aug, 2019
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

FPH Dividend Payments

EX-Date Dividend Amount

FPH Dividends (last 11 Years)